Podcasts about mounjaro

GLP-1 medications like Ozempic, Wegovy, and Mounjaro are everywhere right now — but are they really the solution for women over 40, or just another shiny trend? In this episode, I share what I've seen firsthand with clients: women who saw zero results, women who lost muscle mass and ended up terrified about regaining weight, and women who learned how to use GLP-1s as a temporary tool — and then get off them faster, with healthier, sustainable results. I'm also talking about something that really disturbs me: the current fad of coaches and influencers hyping these drugs as just another angle to sell themselves. Midlife women deserve better than gimmicks — they deserve real solutions that last. If you've ever wondered whether GLP-1s are a quick fix or a true foundation for change, this one's for you. ⏱️ Timestamps 0:00 – The GLP-1 hype is everywhere 2:05 – What I've seen with clients on meds 4:25 – The problem with weight loss vs. muscle loss 6:50 – How women successfully titrated off GLP-1s 8:45 – Why influencers push GLP-1s as the new marketing angle 10:55 – The “bucket vs. roof” analogy (quick fix vs. foundation) 14:10 – My final take: GLP-1s as a tool, not the foundation Join my new KICKSTART here: https://go.loridoddy.com/metabolic-kickstart-vsl/   When you're ready, here's how I can help you for FREE: (Community + Support) Join my Lori Doddy's Total Wellness community to get research-backed tips, strategies, and free resources to lose weight and manage menopause like  (Lose Fat) Steal my guide with exact 5 Changes I have all clients make in week 1 of working with us, so they lose weight and drop inches even before we put their customized plan in place. Get the guide for free and use it this week!  (Toned Arms) Use these 6 moves to get toned, strong, sexy arms in 15 minutes a day, 2-3 days a week with this guide to Sexy, Strong Arms. (Email List) Sign up to get my tips and strategies plus exclusive content by getting on the LDL Email List!  

Will SpaceX's latest triumph mean Elon Musk will make it to Mars? Why will the price of Mounjaro weightless drugs go up? Benjamin Netanyahu called the IDF's airstrike on Gaza's Nasser Hospital a “tragic misstep" but so far 240 Palestinian journalists have died since the beginning of the conflict.Giles Whittell is joined by the Observer's International Editor, Steve Bloomfield, our Acting National News Editor, Rebecca Myers and reporter, James Tapper, as each try to pitch the top story of the day.Links to the team's Must Reads and recommendations here: Race Across the World‘House of Earth and Blood' by Sarah J. Maas**We want to hear what you think! Email us at: newsmeeting@observer.co.uk Follow us on Social Media: @ObserverUK on X @theobserveruk on Instagram and TikTok@theobserveruk.bsky.social‬ on bluesky Host: Giles WhittellProducer: Amalie SortlandExecutive Producer: Rebecca MooreTo find out more about The Observer:Subscribe to TheObserver+ on Apple Podcasts for early access and ad-free contentHead to our website observer.co.uk Download the Tortoise app – for a listening experience curated by our journalists Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Heart to Heart podcast, Dr. Mike Hart hosts Dr. Chester Sokolowski, a peptide expert and the founder of Thrive Telehealth Clinic, which specializes in hormone replacement therapy (HRT) and peptide treatments for both men and women. Dr. Sokolowski discusses his background, career, and various business ventures focused on human performance and optimization. The conversation delves deep into the benefits and applications of testosterone replacement therapy (TRT), peptides, and other health-related topics. Key points include the implications of TRT, managing estrogen levels, the benefits of combining peptides for muscle growth and recovery, and the groundbreaking potential of GLP-1 agonists like Ozempic and Retatrutide for weight loss and metabolic health. Dr. Sokolowski also touches on the benefits of glutathione, the latest research on peptides such as BPC-157 and TB-500, and the ethical considerations of using these therapies in professional sports. Dr. Chester Sokolowski is a performance optimization expert, telehealth clinician, and leading voice in hormone and peptide therapy. He earned his doctoral training at Florida State University and has dedicated his career to human performance, healthspan, and longevity. Known online as “Dr. Soko”, he shares cutting-edge insights on testosterone therapy, peptides, recovery, and performance through social media and educational content. His work empowers people to look, feel, and perform at their absolute best. Follow him on Instagram: @dr.soko, LinkedIn: Dr. Chester Sokolowski and YouTube: Dr. Soko Links: TRT (Testosterone Replacement Therapy) Ozempic (Semaglutide) DIM (Diindolylmethane) Oxidative stress & disease   Show Notes: (00:00) Introduction to the Heart to Heart Podcast (02:30) Dr. soko's dissertation on binge drinking and muscle growth (06:00) Cold therapy and hypertrophy (08:00) TRT and arimidex discussion (13:35) “Estrogen is not the enemy; it's actually protective for your heart, your brain, your joints.” (14:30) HCG and fertility (20:00) Peptides and GLP-1 drugs (34:30) Minimizing side effects and dosage strategies (35:30) Understanding GLP-1 mechanisms (36:00) Red aide: the unique GLP-1 (39:00) Visceral fat and GLP-1 effectiveness (41:00) GLP-1s and impulse control (46:30) Glutathione: the ultimate antioxidant (50:30) Peptides for skin and hair health (51:00) Growth hormone peptides: which is best? (55:00) BPC-157 and tb-500: healing peptides (01:00:30) TRT, peptides, and sports (01:03:00) Conclusion and contact information   — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to  cutting through the noise and uncovering the most effective strategies for optimizing health,  longevity, and peak performance. This podcast dives deep into evidence-based approaches to  hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise  protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary.   Beyond health science, we tackle the intersection of public health and politics, exposing how  policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being.   Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen).   If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart  

It's nearly impossible to turn on the television or open a magazine without seeing advertisements for the latest weight loss trend: GLP-1 medications, commonly known as Ozempic, Mounjaro, Wegovy, and Zepbound. Approximately 15 million people are estimated to have tried these drugs for weight loss. However, as with any emerging health trend, it's important to consider whether these medications are safe and cost-effective.What are the risks and benefits of these drugs? Is the pharmaceutical industry providing a quick fix for the approximately 42% (or 100 million) U.S. citizens who are obese? Are these medications the only solution to the obesity epidemic, or are lifestyle and dietary changes essential for long-term success? Dr. Nicole Dorotik joins us in this episode to address these questions and more as we explore the latest trends in the pursuit of health and wellness.Special Guest: Dr. Nicole Dorotik Dr. Nicole Dorotik earned her medical degree from the University of Arizona College of Medicine and completed her residency at Long Beach Memorial Hospital in Long Beach, California. She is board-certified in Family Medicine and has over 20 years of clinical experience. Along with her professional accomplishments, Nicole is the proud mom to three great kiddos. Show notes:Weight Comes Back When You Stop Taking Drugs Like Ozempic, Study Finds.https://www.sciencealert.com/weight-comes-back-when-you-stop-taking-drugs-like-ozempic-study-finds#A new era of weight loss: Mental health effects of GLP-1 drugs.https://www.apa.org/monitor/2025/07-08/weight-loss-drugs-mental-healthRx History: The Rise of GLP-1s.https://www.innovativerxstrategies.com/rx-history-glp1s/Unintended consequences: Weight loss drugs are changing the way consumers buy groceries.https://www.post-gazette.com/business/healthcare-business/2025/08/17/glp1-ozempic-grocery-store-food-price-weightloss/stories/202508070069.

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Today is a Plus SideZ Rewind! Two years ago, we sat down with the one and only Rosie O'Donnell at the dawn of our movement for affordable access to GLP-1 medications & ending the stigma around treating obesity as a disease. Now, as we stand well into season five with thousands of new subscribers, so it's time for a little time-travel! We're bringing you a “Rewind” of that pivotal conversation to let our new listeners hear where it all began and let our longtime supporters see just how far we've come.In this flashback, we revisit that summer of 2023 when the Mounjaro $25 Savings Card Coupon was ending and people were flocking to compound GLP-1 which still had a lot of question marks surrounding it. And the shortage of all GLP-1s was growing. There was no Zepbound or cash pay price or branded vials. It was $1400-1000 a month go get access to branded GLP-1s. With more voices in the conversation today, we're measuring our progress from that. Oh how far we've come! We can now get branded GLP-1 for under $500. That's a ton of movement in a short time. But let's get it lower! Keep the faith. Let's get loud AND change things! ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy Send us Fan Mail!Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Welcome back to The Midlife Mentors! We're shaking things up with a brand new format we're calling Hot Topics.Each month we'll take a look at some of the stories making headlines that we think matter most to us in midlife - whether that's health, money, culture, or just things that get us talking.This week we're diving into the shocking Mounjaro price hike and what it means for people trying to look after their health, the growing Gen X pension gap, and the controversy around L'Oréal hiring an OnlyFans model for a major campaign.Plenty of food for thought, a bit of debate, and of course, our take on what it all means for midlifers like you. So let's get into this month's Hot Topics.Ibiza Retreat: https://themidlifementors.com/retreats/The Midlife Male Handbook available now:AmazonWaterstonesWH Smith Please remember, if you find the show helpful or it makes you laugh, motivates and inspires you - please do like, share and rate us. We don't run ads on the podcast or for the show, because we want to keep it as enjoyable for you to listen as possible. So if you can help us spread the word, we'd be incredibly grateful.For more information about The Midlife Mentors, click the below link:https://linktr.ee/themidlifementors.comTik Tok: @themidlifementorsIG: @midlifementors

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For people who had never been able to lose weight before, suddenly the numbers on the scale were plummeting. And everybody wanted to get their hands on them. Now, in most industries, if a product goes viral like this, it's a golden ticket. And thanks to government-granted monopolies designed to encourage innovation, the big drug companies behind these blockbuster injections are currently the only ones allowed to make them.In theory, anyway. But, what if that explosive demand backfired, opening the door to legal knock-offs? You've maybe seen them - copycats advertised as the same thing as Ozempic. So, what's the difference? And just how legal are they? On today's show - a drug that's changing people's lives is also challenging the traditional way we buy and sell medicine.This episode was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed. It was edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark is Planet Money's executive producer.Listen free at these links: Apple Podcasts, Spotify, the NPR app or anywhere you get podcasts.Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.Help support Planet Money and hear our bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.Music: Source Audio - “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Andrea dives into a topic she's been closely following for a long time: GLP-1 medications like Ozempic, Wegovy, and Mounjaro. As a personal trainer and nutrition coach, she breaks down what GLP-1s are, how they work, their benefits and side effects, and most importantly, whether they serve as a catalyst or a crutch in someone's health journey. Drawing from real-life scenarios, client experiences, and extensive research, Andrea brings a clear, thoughtful perspective to a complex and often controversial subject. This episode offers practical insight for anyone considering GLP-1s or supporting someone who is.Make Fit Simple Podcast is sponsored by KION. Go to Getkion.com/simple for 20% OFFMake it Simple is sponsored by Goodr SunglassesUse code SIMPLE at check out for FREE SHIPPINGhttp://goodr.com/MAKEITSIMPLEStudies: https://diabetesjournals.org/care/article/48/2/292/157724/Efficacy-of-GLP-1-Receptor-Agonists-on-Weight-Loss https://www.amjmed.com/article/S0002-9343%2825%2900059-2/fulltext Improved Dementia https://pmc.ncbi.nlm.nih.gov/articles/PMC8864443/   Decreasing Cardiovascular Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10739421/ Gastrointestinal Issues https://pmc.ncbi.nlm.nih.gov/articles/PMC10557026/-  Addictions https://www.nature.com/articles/s41591-024-03412-w   PODCASTS on GLP-1 https://podcasts.apple.com/us/podcast/just-ingredients/id1557557205?i=1000679752979 https://podcasts.apple.com/us/podcast/the-dr-tyna-show/id1577258582?i=1000709323014 https://podcasts.apple.com/us/podcast/the-dr-tyna-show/id1577258582?i=1000681609168  Follow the Make Fit Simple Podcast@MakeFitSimplePodcastHave a suggestion for a topic click HEREHave a suggestion for a guest click HERENEW! Leave a question for Andrea HERE on SpeakPipe! Follow Andrea on Instagram@deliciouslyfitnhealthy@dfh.training.picsTraining & Coachinghttps://www.deliciouslyfitnhealthy.com/linksVisit Andrea's Websitewww.deliciouslyfitnhealthy.comProduced by Light On Creative Productions

In this episode, we look at the new "wonder drugs" that are wreaking havoc on people's lives.Show NotesAlcor Life Extension Foundation: https://en.wikipedia.org/wiki/Alcor_Life_Extension_FoundationFred and Linda Chamberlain https://en.wikipedia.org/wiki/Fred_and_Linda_Chamberlain Mike Darwin https://en.wikipedia.org/wiki/Mike_DarwinThe Great Ozempic Scam https://www.theburningplatform.com/2024/09/12/the-great-ozempic-scam Semaglutide https://en.wikipedia.org/wiki/Semaglutide Drug trial snapshot:  https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-ozempic Can Ozempic Kill You? https://www.motleyrice.com/diabetes-lawsuits/ozempic/safe-for-weight-loss/deathsTirzepatide, or Mounjaro https://en.wikipedia.org/wiki/Tirzepatide Tirzepatide is a peptide The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist https://pubmed.ncbi.nlm.nih.gov/37800107/ This Is What Happens When You Inject Yourself With Reptile Venom Peptides Marketed as FDA-Approved Weight Loss Drugs https://discernreport.com/this-is-what-happens-when-you-inject-yourself-with-reptile-venom-peptides-marketed-as-fda-approved-weight-loss-drugs/

Fitzy has discovered a clever hack for landing a job and he’s got the proof that it actually works! With Book Week in full swing, we had to bring in friend of the show Andy Lee, whose Do Not Open This Book series is a favourite for costume inspiration. While he was here, Andy helped Wippa navigate a Mounjaro dilemma, reflected on a radio competition gone wrong, and reignited the fiery Sydney vs. Melbourne rivalry. We also raise a glass as Lynne McGranger's final episode as Irene on Home & Away airs, marking the end of an era as she says goodbye to Summer Bay. And if you're struggling to find motivation today, Fitzy’s got your back with some powerful quotes to fire you up and get you charging into the day!See omnystudio.com/listener for privacy information.

GLP-1 medications like Ozempic, Wegovy, and Mounjaro have become household names, celebrated as breakthrough treatments for weight loss and obesity. But while headlines showcase dramatic before-and-after photos and promises of rapid transformation, when we step beyond the marketing, a more nuanced reality comes to light.In this candid conversation, Dr. Mark Cucuzzella, a family medicine physician, and Dr. Tro Kalayjian, board-certified in internal and obesity medicine, draw on decades of clinical experience to examine where GLP-1s truly shine, where they fall short, and why the foundation for lasting health can't come from a prescription alone.They make the case for integrating GLP-1s into a comprehensive care plan, one that addresses nutrition, movement, sleep, and stress. Without these pillars, patients face higher risks of side effects, reduced long-term benefits, and the all-too-common rebound weight gain.In this interview, you'll learn:Which patients benefit most from GLP-1 therapy (and which may not)How “medication stewardship” ensures safe, responsible useWhy starting at the lowest effective dose and tapering mattersHow lifestyle-first programs can match or exceed drug results at a fraction of the costDrs. Cucuzzella and Kalayjian remind us that true success lies in restoring metabolic health and building habits that last long after the injection ends. GLP-1 medications can be powerful allies, but they're not a silver bullet. Without a foundation of nutrition, movement, sleep, and stress management, they risk becoming just another short-term fix.Expert Featured:Dr. Mark CucuzzellaWebsite: https://www.drmarksdesk.com/Dr. Tro KalayjianWebsite: https://toward.health/IG: https://www.instagram.com/doctortro/X: https://x.com/DoctorTroResources Mentioned:TOWARD: a metabolic intervention that improves addiction and binge eating symptomshttps://doi.org/10.3389/fpsyt.2025.1612551CMEs Mentioned:Managing Major Mental Illness with Dietary Change: The New Science of Hopehttps://www.mycme.com/courses/managing-major-mental-illness-with-dietary-change-9616Brain Energy: The Metabolic Theory of Mental Illnesshttps://www.mycme.com/courses/brain-energy-the-metabolic-theory-of-mental-illness-9615Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/About us:Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education,...

Episode 2685 - Vinnie Tortorich and Anna Vocino discuss the abuse of weight loss drugs, understanding sugar in your body, and more. https://vinnietortorich.com/2025/08/understanding-sugar-episode-2685 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH ALL THE PODCAST EPISODES ON YOUTUBE - Abusing Weight Loss Drugs Vinnie has been travelling lately on a long road trip. (2:00) They discuss how they pack snacks for a road trip. There is some concerning behavior surrounding the use of Mounjaro. (9:30) Rather than eating healthy, people still want to eat poorly, but ramp up the usage of the drug. There is an emotional component behind overeating. (12:30) Understanding Sugar Why is sugar so bad? (21:45) They discuss macros and how much sugar your body needs at any one time. (23:00) If you don't load your body with carbs, then your body will burn fat, which is a good thing. The amount of sugar you need varies depending on your activity. (25:00) For example, a boxer in the ring will burn through sugar very fast. However, there are many activities where your body can produce what it needs with gluconeogenesis. Any extra sugar is stored as fat, or long-chain triglycerides. According to a recent interview Vinnie had with Dr. Tro, it's not uncommon for people to be on 19 medications. (29:00) The national average is 8 drugs. Vinnie explains complex carbs and the myth that claims they are better for you. (33:00) A glycogen load is bad because it causes your body to continually release insulin. Grains are starches, and starches are sugar. However, don't become carb-phobic. That's where Vinnie's rule of Life Into Living (LIL) comes in. (37:00) If you are in Italy, have the gelato: meaning on a truly special, limited occasion, enjoy yourself. Just don't let LIL become frequent or rampant. They chat about travelling and Chamonix. (40:00) Eat Happy Kitchen is for everyone, and several of the sauces are vegan. (46:30) Anna's sauces are in several stores. Go to her website and use the store locator to find the store closest to you. Keep listening because Anna will be sharing new wings recipes for Football season! (54:00) Vinnie explains how you'll be able to join the NSNG® VIP group when it reopens soon! If you are interested in the NSNG® VIP group, register here! More News If you are interested in the NSNG® VIP group, register here! Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it! Eat Happy Italian, Anna's next cookbook, is available!  You can go to You can order it from . Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day! There's a new NSNG® Foods promo code you can use! The promo code ONLY works on the NSNG® Foods website, NOT on Amazon. https://nsngfoods.com/   PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere: Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere: REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere: FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere:

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Today we're talking about one of the body's most powerful secret weapons for weight loss, blood sugar balance, cravings, and even inflammation. It's not a pill. It's not a fad. It's a now famous hormone your body makes naturally — and its name is GLP-1.If that sounds familiar, it's probably because you've heard about drugs like Ozempic®, Wegovy®, or Mounjaro® — all of which are GLP-1 agonists. These drugs mimic GLP-1 in the body to help people feel full longer, eat less, and lose weight. And yes, they work. But they come with a price — financially and physically — and they're not always a long-term solution.Here's the good news: your body already makes GLP-1 on its own. And with the right diet, lifestyle, and a little knowledge, we can help you naturally enhance your own production — safely and sustainably.So today, , we're going to cover the top 10 natural GLP-1 boosters that you can start using right away — no prescription needed.

GLP-1 medications such as Ozempic and Mounjaro are transforming lives, yet there is another side to the story that rarely appears on social media. In this episode, Chalene Johnson examines how influencer culture, black-market “research chemicals,” and questionable compounding pharmacies are profiting from the growing demand. She explores the risks of rapid weight loss that can quietly diminish muscle mass and the rise of MLM-style promotions aimed at midlife women. Listeners will gain insight into the realities behind the trend and learn ways to avoid potentially dangerous shortcuts. Watch this episode on YouTube this Sunday!!  https://www.youtube.com/@chalenejohnson/videos  

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Morse code transcription: vvv vvv Girl who died after Maidenhead hospital failure unlawfully killed Pupil who invented device to help homeless named girl of the year Teenager arrested after death of 13 year old girl in Huddersfield AI designs new superbug killing antibiotics for gonorrhoea and MRSA A level results Why did boys outperform girls for top grades Left out of Alaska talks, Ukrainians fear an unjust peace Cost of weight loss drug Mounjaro may rise significantly VJ Day 80th anniversary King Charles says heroes will never be forgotten Ukraine war US and Russian delegations head to Alaska for crunch talks MasterChef Second contestant edited out of Gregg Wallace and John Torodes final series

Kristina Partsinevelos opens with the market theme before Rick Santelli breaks down bond market reaction to the latest PPI. Steve Liesman explains what drove the number. Former Fed Governor Frederic Mishkin shares insight on the economy and the Fed's next steps.Earnings focus turns to Applied Materials, while our Leslie Picker covers 13F filings. Bob Elliott of Unlimited and Kristina Hooper of Man Group weigh in on market direction, and Chris Retzler of Needham highlights a big week for small caps. Angelica Peebles reports on Eli Lilly raising Mounjaro prices in Europe in response to Trump's pressure. 

As Alaska awaits the arrival tomorrow of the US and Russian Presidents, we're in Anchorage for a preview of their summit - and hear what one Ukrainian woman in the north-eastern city of Kharkiv expects from it.Also on the programme:Why has the pharmaceutical giant Eli Lilly decided to hike the price of the weight loss drug Mounjaro in the UK?Israel says it will push ahead with plans to build more settlements in the West Bank. We have Palestinian reaction.And the A-level student spending results day evening at her local pub - because she runs it. We speak to the UK's youngest pub landlady.

It's part 2 of the GLP 1 deep dive! In this episode, we are covering “food noise,” the weird things that people are reporting happening to their bodies on GLP-1s, horrid stuff that's happening in the UK, lawsuits, safety planning for those taking the drugs, and whether taking GLPs goes against fat liberation. TW: for British anti-fatness, side effects, and mental health. Episode show notes: http://www.fiercefatty.com/200 Support me on Ko-Fi and get the Size Diversity Resource Guide: https://kofi.com/fiercefatty/tiers Ragen's 3 bullet points on GLPs: https://www.instagram.com/p/DKa5xdovYxa/?igsh=bHh1Nml0NW82bG83 https://www.cnn.com/2024/05/02/health/wegovy-weight-loss-drug-new-prescriptions Changes smell: https://www.instagram.com/p/DL0fFPER4QX/?img_index=7&igsh=Mmttb3Y4cG10dHUx The Community Ozempic Stole: As Influencers Lose Weight, Their Followers Feel "Abandoned": https://www.teenvogue.com/story/community-ozempic-stole-influencers-lose-weight Ozempic's Origin Story is Insane: https://youtu.be/9dMpY-ZALXc?si=lb6r-d08fEo9XVKB Dr Rachel Millner: Some thoughts about GLP-1s for intentional weight loss versus fat liberation as a value: https://www.instagram.com/p/DLzrBuuRqfW/?img_index=6&igsh=ODZpMmwyemlhdmxt Another post from Rachel she describes the side effects of GLPs when taken at a higher dose for weight loss and anorexia side effects/complications: https://www.instagram.com/p/DLOUiFKI8TB/ Retatrutide study: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 Ragen's blog: https://weightandhealthcare.substack.com/p/weight-loss-drug-cage-match-part The Race Is On to Stop Ozempic Muscle Loss: Gym chains, nutrition startups and drugmakers all want to solve a common issue among people who take weight loss drugs. Non paywall link: https://archive.ph/l25L9 https://www.nytimes.com/2024/02/08/well/live/ozempic-muscle-loss-exercise.html?utm_source=pocket_mylist The Race Is On to Stop Ozempic Muscle Loss: Gym chains, nutrition startups and drugmakers all want to solve a common issue among people who take weight loss drugs. Non paywall link: https://archive.ph/l25L9 https://www.nytimes.com/2024/02/08/well/live/ozempic-muscle-loss-exercise.html?utm_source=pocket_mylist Changes smell: https://www.instagram.com/p/DL0fFPER4QX/?img_index=7&igsh=Mmttb3Y4cG10dHUx Hannah from Queenbeastsays, The Labour Government wants Britain to be "fat-free" by 2035: https://queenbeastsays.substack.com/p/the-labour-government-wants-britain?utm_source=app-post-stats-page&r=2qfqs8&utm_medium=ios&triedRedirect=true Contraception warning over weight-loss drugs after dozens of pregnancies: UK watchdog has had 40 reports relating to pregnancies in people using drugs such as Ozempic and Mounjaro https://www.theguardian.com/society/2025/jun/05/contraception-warning-over-weight-loss-drugs-after-dozens-of-pregnancies NPP Weight Loss Medications and Safety Planning: https://www.patreon.com/c/nalgonapositivitypride/home 7,000 potential claims already under active investigation Lawsuit Legal News+2Doyle APC Law Firm+2Darrow AI+2.

The GLP-1 Circle Membership Waitlist: https://gianna-beasley-registered-dietitian.ck.page/83c1da4a2f ✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

GLP-1s like Ozempic, Wegovy, and Mounjaro are everywhere right now—on social media, in ads, and maybe even in your own medicine cabinet. Are they magic? Are they cheating? Maybe even wondered should YOU be on one?In this long-overdue episode, I'm cutting through the confusion with my honest, no-BS take on GLP-1 medications—what they actually do (and what they absolutely don't), the biggest myths no one's talking about, and my real thoughts as a weight loss dietitian and coach. I'm sharing stories from real clients, the muscle loss nobody warned you about, and what you actually need to focus on if you want long-term, sustainable results—GLP-1 or not.We're talking appetite vs. emotions, why so many women regain weight after stopping meds, and the non-negotiable mindset shifts you have to make if you want to keep the weight off—plus, my honest answer to “Should I take it?”If you're on GLP-1s, curious about them, or feeling all kinds of ways about this whole convo, this episode is 100% for you. Let's get real about healing your relationship with food and your body, so you can feel FREE—whether there's a prescription in your bag or not.xoxo,JackieMORE FROM JACKIE: >

The GLP-1 Circle Membership Waitlist: https://gianna-beasley-registered-dietitian.ck.page/83c1da4a2f ✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Wegovy, (often referred to as Ozempic) was approved by the FDA in June 2021. Now that we have lived 4 years of a GLP frenzied hellscape, there must be new data on how well GLP1's work and how many lives they have saved. The numbers must be pretty impressive right? Hint: It's not impressive…not at all. Join me for part one of this deep dive into these (not so) new weight loss drugs where I share exactly how much weight people lose, if it improves their health (or worsens it), and all sorts of other nonsense that has been happening in the ensuing years after the press heralded Wegovy as a “game changer” that will “end” fatness. TW: for mentions of weight, mentions of children taking the drug and other general anti-fat ideas. Episode show notes: http://www.fiercefatty.com/199 Support me on Ko-Fi and get the Size Diversity Resource Guide: https://kofi.com/fiercefatty/tiers Ragen's 3 bullet points on GLPs: https://www.instagram.com/p/DKa5xdovYxa/?igsh=bHh1Nml0NW82bG83 https://www.cnn.com/2024/05/02/health/wegovy-weight-loss-drug-new-prescriptions Changes smell: https://www.instagram.com/p/DL0fFPER4QX/?img_index=7&igsh=Mmttb3Y4cG10dHUx The Community Ozempic Stole: As Influencers Lose Weight, Their Followers Feel "Abandoned": https://www.teenvogue.com/story/community-ozempic-stole-influencers-lose-weight Ozempic's Origin Story is Insane: https://youtu.be/9dMpY-ZALXc?si=lb6r-d08fEo9XVKB Dr Rachel Millner: Some thoughts about GLP-1s for intentional weight loss versus fat liberation as a value: https://www.instagram.com/p/DLzrBuuRqfW/?img_index=6&igsh=ODZpMmwyemlhdmxt Another post from Rachel she describes the side effects of GLPs when taken at a higher dose for weight loss and anorexia side effects/complications: https://www.instagram.com/p/DLOUiFKI8TB/ Retatrutide study: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 Ragen's blog: https://weightandhealthcare.substack.com/p/weight-loss-drug-cage-match-part The Race Is On to Stop Ozempic Muscle Loss: Gym chains, nutrition startups and drugmakers all want to solve a common issue among people who take weight loss drugs. Non paywall link: https://archive.ph/l25L9 https://www.nytimes.com/2024/02/08/well/live/ozempic-muscle-loss-exercise.html?utm_source=pocket_mylist The Race Is On to Stop Ozempic Muscle Loss: Gym chains, nutrition startups and drugmakers all want to solve a common issue among people who take weight loss drugs. Non paywall link: https://archive.ph/l25L9 https://www.nytimes.com/2024/02/08/well/live/ozempic-muscle-loss-exercise.html?utm_source=pocket_mylist Changes smell: https://www.instagram.com/p/DL0fFPER4QX/?img_index=7&igsh=Mmttb3Y4cG10dHUx Hannah from Queenbeastsays, The Labour Government wants Britain to be "fat-free" by 2035: https://queenbeastsays.substack.com/p/the-labour-government-wants-britain?utm_source=app-post-stats-page&r=2qfqs8&utm_medium=ios&triedRedirect=true Contraception warning over weight-loss drugs after dozens of pregnancies: UK watchdog has had 40 reports relating to pregnancies in people using drugs such as Ozempic and Mounjaro https://www.theguardian.com/society/2025/jun/05/contraception-warning-over-weight-loss-drugs-after-dozens-of-pregnancies NPP Weight Loss Medications and Safety Planning: https://www.patreon.com/c/nalgonapositivitypride/home 7,000 potential claims already under active investigation Lawsuit Legal News+2Doyle APC Law Firm+2Darrow AI+2.

Eli Lilly (LLY) shares dropped after its latest earnings report and disappointing results for an oral GLP-1 pill. Lee Brown joins Sam Vadas to discuss the phase 3 trial and says "the markets missing the big picture here" believing "tolerability" is the key focal point. He points to the differences in Novo Nordisk (NVO) and LLY weight-loss drug offerings. Lee dives into Mounjaro's cardio-protective results as well, saying it might be "overlooked" in today's report.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Why does joy feel so scary? Why do we hold back when life is good, waiting for something bad to happen? In this episode, I'm sharing why joy is the most vulnerable emotion we can feel and how that fear keeps us from fully living. We'll talk about why our brains default to “what if it all goes wrong,” how this ties into body image and weight loss, and why you don't need a smaller body to feel joy right now.I'm also giving you a personal update from my birthday and what's making me grateful (and a little nervous!) in this season of life. If you've ever struggled to let yourself be happy without guilt or fear, this one's for you.What you'll learn in this episode: ✔ Why joy is the most vulnerable emotion ✔ How fear of losing happiness sabotages your peace ✔ The connection between body image, weight loss, and joy ✔ Practical tips to embrace joy without waiting for the “perfect” moment

The "King Kong" of weight loss drugs, Mounjaro, should finally be available on the NHS. So, why are thousands of patients still waiting for a treatment that could transform their lives? Mounjaro was meant to be rolled out across the NHS in England from 23 June for those with the highest clinical need. However, a Sky News investigation has found it is only available in eight out of 42 NHS integrated care boards, prompting accusations of a "postcode lottery". Many providers will not make it available until autumn, while nearly half of NHS boards said they will cap the number of people they treat due to a lack of funding. Our science and medical correspondent, Thomas Moore, joins Niall Paterson on the Sky News Daily podcast as he investigates how the shortfall will cost the NHS and wider society. Gary, who weighs 25 stone (159kg) and has several obesity-related conditions, speaks to Thomas about the implications of being told Mounjaro is not available in his area. Producer: Emma-Rae Woodhouse and Emily Hulme Editor: Mike Bovill 

Inside INdiana Business Radio for the morning of August 5, 2025. Indiana University receives a $17 million federal grant to establish a cutting-edge brain research center for Alzheimer's. At least 26 patients sue Eli Lilly over alleged side effects of GLP-1 drugs Trulicity and Mounjaro. Also: Construction passes halfway on Rose-Hulman's Innovation Grove, Parkview Health names a new CFO, and Junior Achievement reveals its 2025 Business Hall of Fame laureates. Get the latest business news from throughout the state at InsideINdianaBusiness.com.

In response to the article I wrote in The Times about whether I was daft for not using skinny jabs to lose weight, I thought revisiting my conversation with Johann Hari about his book Magic Pill, which extensively researched the benefits, limitations and risks of GLP-1 Agonist drugs such as Ozempic, Semaglutide, Wegovy and Mounjaro.Johann is thorough and meticulous in his research and this interview, originally broadcast in 2024, was before weight loss drugs became as mainstream and as widely prescribed as they are today.One of the experts Johann interviewed during his years of research, stated that the cultural impact of GLP-1s was as significant as the smart phone. At the time, it seemed like a very bold statement, but in the year since we spoke, I think it's hard to argue that they haven't completely changed the way we talk about weight, weight loss, diets, food and more...I'd love to hear your thoughts on this episode. Email me at office@emmaguns.com or Subscribe to my Substack and join the chat there. Hosted on Acast. See acast.com/privacy for more information.

Oprah Winfrey is returning to Australia on a speaking tour across the nation, which is sponsored by medicine company Lilly who are well-known for their weight loss drug Mounjaro.See omnystudio.com/listener for privacy information.

Inside Martha's Vineyard African American Film Festival; Reaction to Trump's sweeping new tariffs for trade partners; Diabetes drug Mounjaro shows heart benefits: Study Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the Surpass CVOT trial, which evaluates the cardiovascular outcomes of Monjaro compared to Dulaglutide (Trulicity). They delve into the significance of the trial, the implications of the results, and the potential benefits of Monjaro for patients with type 2 diabetes and cardiovascular risks. The conversation highlights the importance of understanding cardiovascular outcome trials and the evolving landscape of diabetes medications.Takeaways: The Surpass CVOT trial compares Mounjaro to Dulaglutide.Dulaglutide has shown cardiovascular benefits in previous trials.The trial results indicate Monjaro is at least not inferior to Dulaglutide.There is a trend towards better cardiovascular outcomes with Mounjaro.Weight loss and glycemic control are significant benefits of Mounjaro.The trial did not include a placebo, but used a putative analysis.The results are reassuring for patients at high cardiovascular risk.The conversation emphasizes the importance of comprehensive treatment for metabolic diseases.The hosts express enthusiasm for the potential of Mounjaro.Future discussions will delve deeper into the trial's findings.      

Inside Martha's Vineyard African American Film Festival; Reaction to Trump's sweeping new tariffs for trade partners; Diabetes drug Mounjaro shows heart benefits: Study Learn more about your ad choices. Visit podcastchoices.com/adchoices

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Biogen's sales of the partnered Alzheimer's drug Leqembi have climbed 20% in the second quarter, while CEO Chris Viehbacher dismisses rumors of disagreements with Eisai. Moderna has cut 10% of its global workforce as part of cost-cutting measures. AbbVie is celebrating the success of Skyrizi and Rinvoq, Lilly's Mounjaro shows promise in a cardiovascular trial, and there is optimism around Sarnas for therapeutic breakthroughs. Amidst industry challenges, many biopharma professionals are looking for new job opportunities.

Triforce! Episode 327! Pyrion creates a vicious The Platform-esque utopian society for pigeons, shares his story of getting onto the weight loss drug Mounjaro and shares some amazing stories of the greatest con artists! Support your favourite podcast on Patreon: https://bit.ly/2SMnzk6 Music courtesy of Epidemic Sound. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Meshel Laurie is an Australian podcaster and author who used to be 160kgs but thanks to gastric sleeve surgery and Mounjaro weight loss jabs she lost a bunch of weight. She reached out because she wants to join Kyle's fatty club and help motivate him. See omnystudio.com/listener for privacy information.

In this week's Five Minute Friday, Dr. Kay dives into the hot topic of Ozempic Face — the facial volume loss and sagging that can occur with rapid weight loss from GLP-1 medications like Ozempic, Wegovy, and Mounjaro. She explains what causes these changes, how to recognize the signs, and when to take action. Learn how strategic filler placement, collagen-stimulating injectables like Radiesse, Sculptra, and Renuva, and preventative planning can help restore youthful structure and preserve your facial foundation. Whether you're just starting weight loss or already seeing changes, this episode is your guide to looking as vibrant as you feel.

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are reshaping how we treat obesity — but there's so much confusion and stigma. That's why we sat down with leading obesity specialist Dr. Spencer Nadolsky for an honest, empowering conversation.We break down how GLP-1s actually work, why food noise is real, and what people aren't being told about compounded semaglutide, weight regain after bariatric surgery, and long-term success.If you've felt frustrated, misunderstood, or stuck — this episode is for you. Whether you're post-op, on medication, or considering your options, this episode brings science, support, and real talk together.

If I wanted to gain back 70 pounds, I know exactly what I'd do because I've lived it. In this episode, I'm sharing the habits, behaviors, and sneaky thought patterns that kept me stuck for years…and would absolutely pack the weight back on if I let them. From zombie eating and isolating myself to living in stretchy pants and giving in to my inner fat bitch voice, we're calling it ALL out.If you've been slipping back into these patterns or feel disconnected from yourself, this episode is your wake-up call. 

Click here to text us!Hello friends! In this episode, I am delighted to have Dr. Sarah Stombaugh on the podcast. We explore the popular GLP-1 medications you may have heard about—Ozempic, Wegovy, Mounjaro—and talk about how they work, who they're designed for, and what makes them effective. We also unpack some of the concerns around these medications, including who should avoid them and what needs to be in place for long-term success.Dr. Stombaugh explains how these medications fit into a much bigger picture that includes nutrition, movement, sleep, and stress management. For women in perimenopause and menopause who are seeing changes in their weight and metabolism, this conversation offers clarity and reassurance. Whether you've struggled with weight your whole life or are seeing shifts for the first time, you'll find helpful information here.We also talk about Dr. Stombaugh's excellent online resource, The GLP Guide, created to support people using these medications outside of a comprehensive care program.Dr. Stombaugh's approach is science-based, compassionate, and refreshingly practical. I think you're going to love what she shares.Show Notes:Grab the Breakfast Guide Here!Connect with Sarah Stombaugh, MD on:Dr. Stombaugh's GLP GuideDr. Stombaugh's InstagramDr. Stombaugh's Tiktok Dr. Stombaugh's FacebookConquer Your Weight Podcast - AppleConquer Your Weight Podcast - SpotifyWays to Connect with Me:InstagramLinkedInWebsiteYouTube...Are you a professional woman over age 50 who's ready to lose weight for the last time? Join the Vibrant-MD weight loss course.Not sure if the Vibrant-MD weight loss course is right for you? Schedule a time to talk with Dr. Heather Awad directly to learn more.Sign up for our FREE course to get the step-by-step roadmap to permanent weight loss. You'll get a new formula that truly works for professional women over age 50, because it's long overdue that we say GOODBYE to the lousy old counting games.

GLP-1 medications like Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) have transformed treatment for type 2 diabetes and weight loss — but they can also cause digestive side effects like nausea, diarrhea, constipation, bloating, and stomach pain that leave many patients confused or worried. In this episode, we're joined by Dr. Catherine Hudson from LSU Health New Orleans to separate fact from fiction and provide clear, evidence-based guidance. Dr. Hudson breaks down: How GLP-1 receptor agonists work Common digestive side effects—and how to manage them Why lifestyle changes still matter What you need to know before surgery or GI procedures when taking these medications Whether you're a patient, caregiver, or healthcare provider, this episode offers practical insights to help you navigate the GLP-1 journey with confidence. This episode is presented in collaboration with the American College of Gastroenterology's Patient Care Committee.  

Weight loss injections are a huge story in the diet world right now. This is a special episode of the podcast, where we hear from people who have experience of using the Mounjaro and Wegovy jabs. You'll get stories from people have had good, bad and every other kind of experience with injections. Some of our contributors have got their jabs via the NHS, others have sourced them privately. We have information about the costs involved, should you want to do the same. Plus we hear from people who have chosen not to try the jabs and why. Send us a voicenote: 07468 286104 If you'd like to mark your weight loss with our exclusive certificates, get Extra Portions of this podcast and win CASH PRIZES go to patreon.com/noshameinagain or find us on the Patreon app. Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Irresistible You podcast, we're diving into what it means to embrace your cozy or “soft life” era, without the guilt. I used to think that doing cozy things like diamond painting or relaxing at home was lazy… or worse, that stillness would lead to weight gain. I thought if it didn't make money or burn calories, it was a waste of time. But now I know better.I'm sharing how I've started doing things that pull me rather than constantly pushing myself and how that shift has helped me stop emotional eating, feel more grounded, and finally listen to my body. Cozy isn't laziness, it's restoration.If you've ever felt stuck between hustle culture and burnout, this episode is for you.

Welcome to my Summer Throwback Playlist—a handpicked collection of the most downloaded episodes of the podcast. These are listener favorites, packed with insights, laughs, and empowered eating encouragement to keep you fueled all summer long. A quick heads up: since these are throwbacks, you might hear old references to programs or events that are no longer active—but the heart of each episode still hits. Let's dive in and revisit the best of the best! In this episode, we're diving into one of the most talked-about weight loss medications on the market: Ozempic—also known by names like Wegovy and Mounjaro. You've likely seen the buzz: celebrity endorsements, dramatic TikTok before-and-afters, and headlines calling it a “miracle drug.” I've had clients take it, ask about it, swear by it, and question it. I've also heard from colleagues with very strong opinions on both sides. So, what's the truth? What is Ozempic really designed for? How does it work? Does it actually help with weight loss? And most importantly—is it safe? I'm sharing a brief overview of the science, my clinical observations, and why this conversation matters—especially in a world where body image, quick fixes, and long-term health often clash. ⚠️ Trigger Warning: If you're currently struggling with or recovering from an eating disorder, please listen with care or consider skipping this episode. Ozempic is contraindicated for anyone with a history of eating disorders. Want to go deeper? I reference two excellent episodes that continue this conversation: "Science Vs." and "Honestly".

Broadcast from KSQD, Santa Cruz on 7-10-2025: Dr. Dawn responds to an email about lion's mane mushroom blood thinning properties. Lion's mane contains hericenones that inhibit platelet aggregation but promote nerve cell growth. People on blood thinners like Eliquis or those with bleeding disorders should stop these supplements before surgery. She recommends lion's mane for cognitive preservation effects despite bleeding risks, emphasizing the need to balance benefits versus risks. An emailer asks about Fatty15 (C15:0 pentadecanoic acid) supplements marketed for longevity. Dr. Dawn finds promising research, however, most studies are in animals with limited human data. She warns against over-supplementation and recommends food-first approaches, suggesting cheaper alternatives like berberine may provide similar benefits. A visiting guest asks about continuing L-arginine after blood pressure normalized. Dr. Dawn recommends continuing L-arginine as it helps produce nitric oxide and prevents age-related arterial stiffening. She explains how blood vessel elasticity decreases with age, creating feed-forward cycles leading to permanent hypertension. The guest also asks about iodine safety - Dr. Dawn confirms 1mg daily is safe, noting Japanese populations consume up to 4mg daily without problems. Another visiting guest inquires about memory-boosting supplements (nootropics). Dr. Dawn identifies nicotine and caffeine as effective options, mentioning she uses nicotine patches for test-taking focus. She discusses lion's mane as effective for cognitive enhancement and coffee blends combining both ingredients. A caller asks about tirzepatide (Mounjaro) for weight loss at age 73, concerned about muscle loss. Dr. Dawn emphasizes the importance of branched-chain amino acids and 20-30 grams of protein before exercise for older adults to build muscle protein. She explains younger people can build muscle while fasting, but older adults need circulating protein during exercise to activate muscle-building DNA. She recommends alternating upper and lower body workouts and checking testosterone levels. Another caller asks about rapid resting pulse rate (80-100 bpm) at age 74. Dr. Dawn suggests checking blood pressure, as low blood pressure can cause compensatory heart rate increases. She explains age-related changes in blood vessel reflexes that can cause blood pooling in legs and orthostatic changes. The caller also complains about pharmaceutical advertising, prompting Dr. Dawn to criticize direct-to-consumer drug marketing for creating artificial needs through emotional manipulation. Dr. Dawn warns against P-Tau217 blood testing for Alzheimer's screening, calling it inadequate for general population screening. The test has poor predictive value below level 10, creating many false positives in low-risk populations. She criticizes associated drugs like donanemab (Kisunla) for severe side effects including brain swelling and hemorrhage. Instead, she recommends lifestyle interventions: exercise, stress control, adequate sleep, reduced alcohol and sugar intake for memory concerns. She criticizes FDA approval of a new blood test for colon cancer screening with 83% sensitivity for detecting existing cancers but poor sensitivity for precancerous polyps. Dr. Dawn criticizes this as inadequate screening since it detects cancer after "the horse has left the barn" rather than preventing it. In closing remarks with her impromptu guests, Dr. Dawn addresses a question about intermittent fasting and exercise timing. She explains that exercising while fasting provides cardiovascular benefits but won't build muscle mass in older adults. She recommends bioimpedance analysis testing to track lean body mass annually in seniors and emphasizes the importance of progressive resistance training to prevent age-related muscle loss.

This week, we're diving into the stories shaping what we eat, how we shop and the way we live. We're talking about the government's new push to tackle obesity by cutting just 50 calories a day, whether weight-loss jabs like Wegovy and Mounjaro are already changing our shopping habits, and the latest on possible bans or tighter rules for alcohol advertising in the UK. We also get into which oils you actually want to be cooking with at home, why M&S has just trademarked something called “Punishment Juice,” and a major new NHS survey that reveals one in four young adults are now living with a mental health condition. Plus, could creatine help prevent Alzheimer's? We look at what the science says so far — along with all our personal updates and this week's recommendations, from cult podcasts to berry-packed smoothies. This week's recs: Korean exfoliating mitt⁠ ⁠How I Became a Brainwashed Cult Bride⁠ on Conversations (ABC Australia) Get your copy of Rhi's new book 'The Unprocessed Plate' ⁠⁠HERE⁠ Vote for us to win the Listener's Choice award at the British Podcast Awards: https://www.britishpodcastawards.com/voting Learn more about your ad choices. Visit podcastchoices.com/adchoices